Radium-223 international early access program: results from the Spanish subset

To report results from the Spanish subset included in the radium-223 international early access program (iEAP).

Ninety patients with castration-resistant prostate cancer and bone metastases received radium-223 55 kBq/kg every 4 weeks for six cycles.

The median time to disease progression was 8 months and to prostate-specific antigen progression was 4 months. The percentage of patients with ≥50% confirmed declines in prostate-specific antigen was 9%. The median overall survival was 14 months. Grade 3 or 4 treatment emergent adverse events (TEAEs) occurred in 34% of patients (serious TEAEs 28%, TEAEs leading to discontinuation 27%).

Outcomes of the Spanish subset are consistent with the iEAP. Radium-223 was generally well tolerated with no safety concerns.

Future oncology (London, England). 2017 Dec 13 [Epub]

Joan Carles, Mª José Méndez, Álvaro Pinto, Mª Isabel Sáez, José A Arranz, Pablo Maroto, Pilar López-Criado, Begoña Mellado, Jesús García Donas, Susana Hernando, Luís León, Aránzazu González Del Alba, Núria Laínez, Emilio Esteban, Gaspar Reynés, José L Pérez-Gracia, Josep R Germà, Marta López-Brea, Begoña Pérez-Valderrama, Cristina Moretones, Daniel Castellano

Department of Medical Oncology, Hospital Universitario Vall d'Hebrón, Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain., Department of Medical Oncology, Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofía Hospital, University of Córdoba, 14004 Córdoba, Spain., Department of Medical Oncology, Hospital Universitario la Paz, 28046 Madrid, Spain., Department of Medical Oncology, Hospital Universitario Virgen de la Victoria, 29010 Málaga, Spain., Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain., Department of Medical Oncology, Hospital de la Santa Cruz y San Pablo, 08041 Barcelona, Spain., Department of Medical Oncology, MD Anderson Cancer Center, 28033 Madrid, Spain., Department of Medical Oncology, Hospital Clínico y Provincial, 08036 Barcelona, Spain., Department of Medical Oncology, CIOCC, 28050 Madrid, Spain., Department of Medical Oncology, Hospital Universitario Fundación Alcorcón, 28922 Madrid, Spain., Department of Medical Oncology, Complejo Hospitalario Universitario de Santiago, 15706 Santiago de Compostela, Spain., Department of Medical Oncology, Hospital Universitario Son Espases, 07120 Palma de Mallorca, Spain., Department of Medical Oncology, Complejo Hospitalario de Navarra, 31008 Pamplona, Spain., Department of Medical Oncology, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain., Department of Medical Oncology, Hospital Universitario y Politécnico la Fe, 46026 Valencia, Spain., Department of Medical Oncology, Clínica Universidad de Navarra, 31008 Pamplona, Spain., Department of Medical Oncology, Instituto Catalán de Oncología, 08908 Hospitalet de Llobregat, Spain., Department of Medical Oncology, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain., Department of Medical Oncology, Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain., Bayer Hispania SL, 08970 Barcelona, Spain., Department of Medical Oncology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe